Astellas Pharma Canada, Inc.
24
0
1
18
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
8.3%
2 terminated/withdrawn out of 24 trials
90.0%
+3.5% vs industry average
50%
12 trials in Phase 3/4
33%
6 of 18 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (24)
A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf
Role: collaborator
Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts
Role: collaborator
The Living Kidney Donor Safety Study
Role: collaborator
Once Daily Dosing to Improve Medication Adherence and Patient Satisfaction in Kidney Transplant Recipients
Role: collaborator
Effect of Laparoscopic Sleeve Gastrectomy in the Morbidly Obese, Kidney Transplant Candidate
Role: collaborator
Comparison of Medication Adherence Between Once and Twice Daily Tacrolimus in Stable Renal Transplant Recipients
Role: collaborator
Evaluation Of Switching From Twice Daily Tacrolimus To Once Daily Formulation On Cardiovascular Risk
Role: collaborator
Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens
Role: collaborator
Tacrolimus as Secondary Intervention vs. Continuation of Cyclosporine in Renal Transplant Patients With Chronic Renal Allograft Failure (CRAF)
Role: collaborator
Role of T Helper 17 and Regulatory T Cells in Delayed Graft Function
Role: collaborator
Validation of a Novel Diagnostic Tool for the Evaluation of Post Renal Transplant Immunosuppression: The ImmuKnow Assay
Role: collaborator
Advagraf/Prograf Conversion Trial
Role: collaborator
Study of Immunosuppressive Therapy Toxicities in Kidney Transplant Recipients at Regional or Satellite Community Clinics
Role: collaborator
Benefit of Early Protocol Biopsy and Treatment of Subclinical Rejection
Role: collaborator
Effect of Rapid Steroid Withdrawal on Subclinical Markers of Rejection
Role: collaborator
Comparison of Extended Release Tacrolimus (Advagraf) and Cyclosporine A Microemulsion on Renal Function in Healthy Volunteers
Role: collaborator
The Risk of Venous Clotting in Patients After Renal Transplant
Role: collaborator
Assess the Long-term Effectiveness and Safety of Amevive (Alefacept) in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Role: collaborator
Assess the Efficacy and Safety of Alefacept With Narrow Band Ultraviolet B Phototherapy (nbUVB) vs. Alefacept Alone in Chronic Plaque Psoriasis Subjects
Role: collaborator
A Comparison of the Effects of Extended Release Tacrolimus (Advagraf®) vs. Immediate Release Tacrolimus (Prograf®) on Kidney Function in Healthy Male Volunteers
Role: lead